TABLE 6.
Sensitivities of uncloned HIV-1 envelopes from subjects before and during BMS-488043 administration to HIV-1 entry inhibitors
| Subject | EC50, nM (n-fold change)a |
|||
|---|---|---|---|---|
| Baseline |
Day 8 |
|||
| Enfuvirtide | Sch C | Enfuvirtide | Sch C | |
| 2 | 2.2 | 3.1 | 1.0 (<1) | 1.2 (<1) |
| 4 | 3.0 | 1.4 | 6.6 (2) | 2.0 (1) |
| 10 | 2.4 | 1.4 | 1.3 (<1) | 1.4 (1) |
| 19 | 4.3 | 2.0 | 4.0 (1) | 1.0 (1) |
| 21 | 5.0 | 2.5 | 5.6 (1) | 1.4 (1) |
| 25 | 1.7 | 1.0 | 1.6 (1) | 1.1 (1) |
| 27 | 4.6 | 1.5 | 11.8 (3) | 1.7 (1) |
| 30 | 5.2 | 1.7 | 5.7 (1) | 1.4 (1) |
a
The n-fold change is the difference between the sensitivities of the baseline and day 8 envelopes to each inhibitor.